Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year highDepomed says shingles pain drug meets study goal MENLO PARK, Calif. — Depomed Inc. on Monday reported a successful late stage clinical trial of a drug intended to treat pain following the viral infection shingles, and its shares soared on the news. |
|